Cargando…
In Vivo Anticancer Activity of AZD3965: A Systematic Review
Proliferating cancer cells have high energy demands, which is mainly obtained through glycolysis. The transmembrane trafficking of lactate, a major metabolite produced by glycolytic cancer cells, relies on monocarboxylate transporters (MCTs). MCT1 optimally imports lactate, although it can work bidi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8746498/ https://www.ncbi.nlm.nih.gov/pubmed/35011413 http://dx.doi.org/10.3390/molecules27010181 |
_version_ | 1784630601062547456 |
---|---|
author | Silva, Ana Antunes, Beatriz Batista, Alberta Pinto-Ribeiro, Filipa Baltazar, Fátima Afonso, Julieta |
author_facet | Silva, Ana Antunes, Beatriz Batista, Alberta Pinto-Ribeiro, Filipa Baltazar, Fátima Afonso, Julieta |
author_sort | Silva, Ana |
collection | PubMed |
description | Proliferating cancer cells have high energy demands, which is mainly obtained through glycolysis. The transmembrane trafficking of lactate, a major metabolite produced by glycolytic cancer cells, relies on monocarboxylate transporters (MCTs). MCT1 optimally imports lactate, although it can work bidirectionally, and its activity has been linked to cancer aggressiveness and poor outcomes. AZD3965, a specific MCT1 inhibitor, was tested both in vitro and in vivo, with encouraging results; a phase I clinical trial has already been undertaken. Thus, analysis of the experimental evidence using AZD3965 in different cancer types could give valuable information for its clinical use. This systematic review aimed to assess the in vivo anticancer activity of AZD3965 either alone (monotherapy) or with other interventions (combination therapy). Study search was performed in nine different databases using the keywords “AZD3965 in vivo” as search terms. The results show that AZD3965 successfully decreased tumor growth and promoted intracellular lactate accumulation, which confirmed its effectiveness, especially in combined therapy. These results support the setup of clinical trials, but other important findings, namely AZD3965 enhanced activity when given in combination with other therapies, or MCT4-induced treatment resistance, should be further considered in the clinical trial design to improve therapy response. |
format | Online Article Text |
id | pubmed-8746498 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87464982022-01-11 In Vivo Anticancer Activity of AZD3965: A Systematic Review Silva, Ana Antunes, Beatriz Batista, Alberta Pinto-Ribeiro, Filipa Baltazar, Fátima Afonso, Julieta Molecules Systematic Review Proliferating cancer cells have high energy demands, which is mainly obtained through glycolysis. The transmembrane trafficking of lactate, a major metabolite produced by glycolytic cancer cells, relies on monocarboxylate transporters (MCTs). MCT1 optimally imports lactate, although it can work bidirectionally, and its activity has been linked to cancer aggressiveness and poor outcomes. AZD3965, a specific MCT1 inhibitor, was tested both in vitro and in vivo, with encouraging results; a phase I clinical trial has already been undertaken. Thus, analysis of the experimental evidence using AZD3965 in different cancer types could give valuable information for its clinical use. This systematic review aimed to assess the in vivo anticancer activity of AZD3965 either alone (monotherapy) or with other interventions (combination therapy). Study search was performed in nine different databases using the keywords “AZD3965 in vivo” as search terms. The results show that AZD3965 successfully decreased tumor growth and promoted intracellular lactate accumulation, which confirmed its effectiveness, especially in combined therapy. These results support the setup of clinical trials, but other important findings, namely AZD3965 enhanced activity when given in combination with other therapies, or MCT4-induced treatment resistance, should be further considered in the clinical trial design to improve therapy response. MDPI 2021-12-29 /pmc/articles/PMC8746498/ /pubmed/35011413 http://dx.doi.org/10.3390/molecules27010181 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Systematic Review Silva, Ana Antunes, Beatriz Batista, Alberta Pinto-Ribeiro, Filipa Baltazar, Fátima Afonso, Julieta In Vivo Anticancer Activity of AZD3965: A Systematic Review |
title | In Vivo Anticancer Activity of AZD3965: A Systematic Review |
title_full | In Vivo Anticancer Activity of AZD3965: A Systematic Review |
title_fullStr | In Vivo Anticancer Activity of AZD3965: A Systematic Review |
title_full_unstemmed | In Vivo Anticancer Activity of AZD3965: A Systematic Review |
title_short | In Vivo Anticancer Activity of AZD3965: A Systematic Review |
title_sort | in vivo anticancer activity of azd3965: a systematic review |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8746498/ https://www.ncbi.nlm.nih.gov/pubmed/35011413 http://dx.doi.org/10.3390/molecules27010181 |
work_keys_str_mv | AT silvaana invivoanticanceractivityofazd3965asystematicreview AT antunesbeatriz invivoanticanceractivityofazd3965asystematicreview AT batistaalberta invivoanticanceractivityofazd3965asystematicreview AT pintoribeirofilipa invivoanticanceractivityofazd3965asystematicreview AT baltazarfatima invivoanticanceractivityofazd3965asystematicreview AT afonsojulieta invivoanticanceractivityofazd3965asystematicreview |